Pharma stock jumps after signing $50 mil licensing & supply agreement for its biosimilar drug
Trade Brains
JULY 9, 2025
Synopsis: Lupin Limited has entered a $50 million licensing and supply agreement with Zentiva to commercialize its biosimilar Certolizumab Pegol across global markets. Lupin has entered into a License and Supply Agreement with Zentiva, k.s., Please consult your investment advisor before investing. What’s the news?
Let's personalize your content